ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues

ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments 26 August 2021 -- Positive high-level results from the FoCus Phase III trial i

Latest News Clinical News 42
Read All

CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 a

Latest News Clinical News 31
Read All

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax

Latest News Clinical News 34
Read All

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

NEW YORK, Aug. 24, 2021 -- Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and ran

Latest News Clinical News 41
Read All

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmace

Latest News Clinical News 40
Read All

AZD7442 PROVENT Phase III Prophylaxis Trial Met Primary Endpoint in Preventing COVID-19

77% reduced risk of developing symptomatic COVID-19 First long-acting antibody combination to prevent COVID-19 20 August 2021 -- Positive high-level results from the PROVENT Phase III pre-exposure pro

Latest News Clinical News 44
Read All

NRx Pharmaceuticals Announces Positive Safety Report for Zyesami (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 6

Latest News Clinical News 42
Read All

Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone Data support the use of toripalimab with chemotherapy as first-line therapy for pa

Latest News Clinical News 40
Read All

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

SOUTH SAN FRANCISCO, August 18, 2021 -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engin

Latest News Clinical News 37
Read All

FDA Approves Trudhesa (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases

Latest News NDA News 39
Read All

FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia

TITUSVILLE, N.J., Sept. 1, 2021 -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsych

Latest News NDA News 35
Read All

Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine

NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 v

Latest News Clinical News 45
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism